# High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/high-efficacy-of-eculizumab-treatment-for-fulminant-hemolytic-anemia-in-primary/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Kenichi Makishima,Naoshi Obara,Kantaro Ishitsuka,Shinichiro Sukegawa,Sakurako Suma,Yusuke Kiyoki,Naoko Baba,Tatsuhiro Sakamoto,Takayasu Kato,Manabu Kusakabe,Hidekazu Nishikii,Naoki Kurita,Yasuhisa Yokoyama,Mamiko Sakata‐Yanagimoto,Yuichi Hasegawa,Shigeru Chiba |
| Citations | 16 |
| DOI | 10.1007/s00277-018-3521-4 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2897186080 |
| PMID | 30324459 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Tatsuhiro Sakamoto](https://scholariq.org/researchers/tatsuhiro-sakamoto/)

## Paper primary topic

- [Blood groups and transfusion](https://scholariq.org/topics/blood-groups-and-transfusion/)

## Paper topics

- [Blood groups and transfusion](https://scholariq.org/topics/blood-groups-and-transfusion/)
- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)
- [Erythrocyte Function and Pathophysiology](https://scholariq.org/topics/erythrocyte-function-and-pathophysiology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.